Innovations in Combination Therapy to Dominate COPD Treatment Market

The chronic obstructive pulmonary disease treatment market is projected to be valued at ~US$ 26.2 billion in the year 2027. The high prevalence of chronic obstructive pulmonary disease (COPD) and the need for improved treatment options are catalyzing market growth.

To meet the needs of patients, healthcare companies in the COPD treatment market are developing efficacious treatment options in combination therapy. Revenue of combination therapy was valued at ~US$ 9.6 billion in 2018; the highest amongst all the drug classes in the chronic obstructive pulmonary disease treatment market.

With increased research & development, healthcare companies are innovating new triple combination therapies. For instance, in June 2019, AstraZeneca — an English-Swedish multinational pharmaceutical company, announced the approval of Breztri Aerosphere — a pressurized metered dose inhaler with built-in triple combination therapy for patients suffering from moderate to severe COPD in Japan. Stakeholders in the chronic obstructive pulmonary disease treatment market are running continuous clinical trials to meet the primary endpoints of the disease.

chronic obstructive pulmonary disease treatment market infographic

To understand how our report can bring difference to your business strategy, Ask for a brochure

Dual and Triple Therapies Minimize Moderate and Severe Exacerbations

With ongoing developments in the chronic obstructive pulmonary disease treatment market, healthcare companies are weighing the responses and combination of therapies in patients. As such, there is a strife between the credibility of dual combination therapy and long acting bronchodilators for treatment in COPD patients.

To achieve greater effectiveness of therapies in the chronic obstructive pulmonary disease treatment market, manufacturers have integrated combinations of bronchodilators to treat patients with moderate to severe COPD. This includes the combination of long acting beta agonist (LABA) with long acting muscarinic antagonist (LAMA). Thus, the LAMA and LABA group of inhalers are considered safe and effective in COPD patients.

Also, triple therapy has shown better outcome in patients as compared to single-agent LAMA monotherapy in the COPD treatment market. Compared with LAMA monotherapy, triple therapy helps to drastically reduce moderate or severe exacerbations. Thus, healthcare companies are making significant improvements to enhance triple therapy against dual therapy LABA/LAMA.

Request a sample to get extensive insights into the Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

Improved Bronchodilators Reduce Reversibility in Patients

Stakeholders in the chronic obstructive pulmonary disease treatment landscape are developing methods to reduce emphysema and the mortality rates of patients. This has instigated the need for combined bronchodilator response (BDR) in patients. Revenue of bronchodilators in the COPD treatment market is estimated to reach a value of ~US$ 5.5 billion by 2027; the second-highest amongst all drug classes. This is why, healthcare professionals are taking regular follow-ups on patients with combined-BDR. However, the results in combined-BDR are associated with greater frequency of exacerbations and symptoms of asthma. Thus, healthcare companies are increasing research to identify patients with asthma-COPD overlaps, and developing treatment alternatives that result in improved outcomes.

Studies published in the European Respiratory Journal stated that, bronchodilator reversibility might not distinguish asthma from COPD. It was also found that, the prevalence of bronchodilator reversibility was higher in patients with COPD than in asthma patients. Thus, with the help of bronchodilator response testing, healthcare companies are developing improved prebronchodilators that minimize the adverse effects in patients.

chronic obstructive pulmonary disease treatment market segmentation

Stuck in a neck-to-neck competition with other brands? Request a custom report on “Chronic Obstructive Pulmonary Disease (COPD) Treatment Market”

Analysts’ Viewpoint on COPD Treatment Market

The chronic obstructive pulmonary disease treatment market is anticipated for high growth during the forecast period. Although retail pharmacies dominate more than half of the market share, online pharmacies are expected to experience steady growth in the market. Healthcare companies are introducing digital inhalers with built-in sensors for patients suffering from COPD. For instance, in December 2018, Teva Pharmaceutical Industries — a leading Israeli multinational pharmaceutical company, announced the launch of ProAir® Digihaler™ — a digital inhaler with Bluetooth wireless technology for patients with asthma and COPD. However, healthcare companies are developing improved therapies to reduce the reversibility of inhalers in patients. Thus, manufacturers should focus on increasing triple therapy treatment options to effectively minimize exacerbations.

Chronic Obstructive Pulmonary Disease (COPD) Treatment Market: Overview

  • According to Transparency Market Research’s latest report on the chronic obstructive pulmonary disease (COPD) treatment market for the historical period of 2017-2018 and forecast period of 2019-2027, increasing burden of chronic obstructive pulmonary disease, rise in geriatric population, and surge in product approvals and launches are expected to boost the global chronic obstructive pulmonary disease treatment market during the forecast period.
  • According to the report, the global chronic obstructive pulmonary disease treatment market was valued at ~US$ 17.4 Bn in 2018. The COPD treatment market is expected to expand at a CAGR of ~5% from 2019 to 2027.

Increase in Prevalence of Chronic Obstructive Pulmonary Disease: A Key Driver of COPD Treatment Market

  • Chronic Obstructive Pulmonary Disease (COPD) is a major health concern affecting a large number of people across the globe. The disease burden is rising, thereby increasing the need for COPD management, and this is anticipated to drive the global chronic obstructive pulmonary disease treatment market.
  • Tobacco smoking could also lead to COPD, as such, boosting the COPD treatment market. The number of adults addicted to smoking has been increasing. Other risk factors include occupation and indoor air pollution. According to the WHO, the primary cause of COPD is exposure to tobacco smoke (either active smoking or passive smoking).
  • According to an article published by Medscape in April 2019, the prevalence of COPD, worldwide, varies between 7 - 19%. The Burden of Obstructive Lung Disease (BOLD) study found a global prevalence of 10.1%. Men have a pooled prevalence of 11.8%, while it has a prevalence of 8.5% in women. The numbers vary across different regions around the world. Cape Town, South Africa, has the highest prevalence, affecting 22.2% of men and 16.7% of women.
  • According to a report by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) published in 2018, the prevalence and burden of COPD are projected to increase in the near future, due to continued exposure to COPD risk factors and aging of the world’s population, which is thereby boosting the growth of the chronic obstructive pulmonary disease treatment market. 

Increase in Adoption of Combination Therapy: A Key Driver of COPD Treatment Market

  • Combination therapy includes LAMA-ICS, LABA-ICS, triple therapy, and other combination drugs, which are anticipated to drive the chronic obstructive pulmonary disease treatment market.
  • The adoption of combination therapy is increasing, as it is more effective than separate use of bronchodilator and corticosteroid. There has been an increase in the number of patients being successfully treated with combination therapy, who were not showing signs of recovery with bronchodilators or corticosteroids treatments, which is thereby boosting the growth of the COPD treatment market.
  • Combination therapy is more effective than monotherapy for improving the symptoms and quality of life.
  • Regulatory authorities such as the FDA, the European Commission, and the Ministry of Health, Labour and Welfare (MHLW), which is a cabinet level ministry of the Japanese government, have approved the use of combination drugs for the treatment of COPD. In November 2018, GlaxoSmithKline plc and Innoviva, Inc. received authorization from the European Commission for the expanded use of once-daily Trelegy Ellipta, the first single inhaler triple therapy indicated for COPD patients who were not adequately treated with dual bronchodilation. These drugs have a longer patent cover, i.e., till 2030, which will lead to high valuation of the chronic obstructive pulmonary disease treatment market.
  • In April 2019, the FDA approved the combination therapy for COPD maintenance. A fixed-dose combination of long-acting muscarinic antagonist (LAMA) aclidinium bromide (400 mcg) and long-acting beta-agonist (LABA) formoterol fumarate (12 mcg) has been approved by the FDA for the maintenance and treatment of chronic obstructive pulmonary disease.
  • Increase in the success rate of combination therapy for COPD treatment and recent regulatory approvals have propelled the adoption of combination therapy in COPD management, thereby boosting the growth of the COPD treatment market.

Patent Expiry of Branded Products and Availability of Generic Equivalents Hamper Market

  • Patents prevent other manufacturers from developing drugs that are being exclusively manufactured by a patent holder. The patent expiry of branded drugs has a significant impact on the pharmaceutical industry.
  • In case of the COPD treatment market, a few of the players face the threat of patient expiry, which further increases the availability of generic versions of drugs and creates pricing pressure on manufacturers.
  • Patent expiry declines revenue generated from the sales of branded drugs, and can affect the market share of a company. For instance, Flixotide/Flovent, Advair, and Serevent are major respiratory products manufactured by GlaxoSmithKline, which are now facing patent expiry. This is likely to lead to a decline in sales, thereby affecting the company’s market position. In January 2019, the FDA approved Mylan's Wixela Inhub, the first generic version of Advair Diskus for the treatment of asthma and COPD.
  • The availability of generic versions of medicines in the market affects the sales of branded drugs in developed regions such as North America and Europe, and causes pricing pressure, as such, restraining the growth of the chronic obstructive disease treatment market.

Global Chronic Obstructive Pulmonary Disease Market: Competition Landscape

  • This report profiles major players in the global COPD treatment market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments

Prominent players operating in the global chronic obstructive pulmonary disease treatment market include

  • AstraZeneca
  • Boehringer Ingelheim International GmbH
  • GlaxoSmithKline plc
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Sunovion Pharmaceuticals Inc. (Sumitomo Dainippon Pharma Co., Ltd.)
  • CHIESI Farmaceutici S.p.A.
  • Orion Corporation
  • ​Mylan N.V.

Global Chronic Obstructive Pulmonary Disease Treatment Market: Key Developments

Key players in the global chronic obstructive pulmonary disease treatment market are engaged in the development of new products, key mergers & acquisitions, collaborations, and integration. Major developments by industry players are likely to fuel the expansion of the global COPD treatment market. Some of the growth strategies adopted by players in the global chronic obstructive pulmonary disease treatment market are as follows:

  • In January 2019, CHIESI Farmaceutici S.p.A. entered into an exclusive global license agreement with TiumBio, a clinical-stage private biotech company based in South Korea. TiumBio specializes in research on innovative drugs for rare diseases. This agreement is aimed at developing innovative molecules for use in the treatment of respiratory diseases.
  • In November 2018, GlaxoSmithKline plc and Innoviva, Inc. announced authorization from the European Commission for the expanded use of once-daily Trelegy Ellipta, the first single inhaler triple therapy indicated for COPD. This expansion would help the company to cater to the treatment needs of COPD patients who were not receiving adequate treated with dual bronchodilation.
  • In March 2015, AstraZeneca acquired Actavis’ branded respiratory business in the U.S. and Canada, with the aim to strengthen its product portfolio in the respiratory business. AstraZeneca owned the rights for branded respiratory drugs such as TudorzaTM PressairTM, Duaklir Genuair, and Daliresp (roflumilast).

The report on the global chronic obstructive pulmonary disease treatment market discusses individual strategies, followed by the company profiles of manufacturers of COPD treatment options. The ‘Competition Landscape’ section is included in the COPD market report to provide readers with a dashboard view and a company market share analysis of key players operating in the global chronic obstructive pulmonary disease treatment market.

Chronic Obstructive Pulmonary Disease (COPD) Treatment Market – Scope of the Report

TMR’s report on the global chronic obstructive pulmonary disease (COPD) treatment market studies the past as well as current growth trends and opportunities to gain valuable insights of the same indicators for the said market during the forecast period of 2019 to 2027. The report provides the overall market revenue of the global chronic obstructive pulmonary disease treatment market for the period of 2017–2027, with 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global chronic obstructive pulmonary disease treatment market during the forecast period.

The report is prepared after extensive research. Primary research involves bulk of the research efforts, wherein, analysts carried out interviews with industry leaders and opinion makers. Extensive secondary research involves referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global COPD treatment market.

Secondary research also includes Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of the top-down and bottom-up approaches to study various phenomena in the global chronic obstructive pulmonary disease treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study. Furthermore, the report sheds light on the changing competitive dynamics in the global chronic obstructive pulmonary disease treatment market. These indices serve as valuable tools for existing market players as well as for entities interested in entering the global chronic obstructive pulmonary disease treatment market.

The report delves into the competition landscape of the global COPD treatment market. Key players operating in the global chronic obstructive pulmonary disease treatment market have been identified, and each one of them has been profiled for their distinguishing business attributes. Company overview, financial standings, recent developments, and SWOTs are some of the attributes of the players in the global COPD treatment market that have been profiled in this report.

Key Questions Answered in the COPD Treatment Market Report

  • What is the scope of growth for companies in the global chronic obstructive pulmonary disease treatment market?
  • What will be the Y-o-Y growth of the global chronic obstructive pulmonary disease treatment market between 2019 and 2027?
  • Will North America continue to remain the most profitable regional market for COPD treatment providers?
  • Which factors will impede the growth of the global chronic obstructive pulmonary disease treatment market during the forecast period?
  • Which are the leading companies in the global COPD treatment market?

Research Methodology

A unique research methodology has been utilized by TMR to conduct a comprehensive research on the growth of the global chronic obstructive pulmonary disease treatment market, and arrive at conclusions on the future growth prospects of the COPD treatment market. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the drawn conclusions.

Secondary sources referred to by analysts during the production of the global chronic obstructive pulmonary disease treatment market report include statistics from company annual reports, SEC filings, company websites, World Bank database, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of TMR’s study on the COPD treatment market as primary sources.

These primary and secondary sources have provided exclusive information during interviews, which serves as a validation from chronic obstructive pulmonary disease treatment market leaders. Access to an extensive internal repository and external proprietary databases allows this report to address specific details and questions about the global chronic obstructive pulmonary disease treatment market with accuracy. The study also uses the top-down approach to assess the numbers for each segment, and the bottom-up approach to counter-validate them. This has helped in reaching TMR’s estimates on the future prospects of the global chronic obstructive pulmonary disease treatment market more reliably and accurately.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

Chronic Obstructive Pulmonary Disease Treatment Market – Segmentation 

Drug Class

  • Combination Therapy
    • Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
    • Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
    • Triple Therapy
  • Others
  • Corticosteroids
  • Phosphodiesterase Type 4 Inhibitors
  • Mucokinetics
  • Bronchodilators
    • Long Acting Beta Agonist (LABA)
    • Short Acting Beta Agonist (SABA)
    • Long Acting Muscarinic Antagonist (LAMA)
  • Others

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

With a robust experience in creating exceptional market reports, Transparency Market Research has emerged as one of the trusted market research companies among a large number of stakeholders and CXOs. Every report at Transparency Market Research goes through rigorous research activity in every aspect. The researchers at TMR keep a close watch on the market and extract beneficial growth-boosting points. These points help the stakeholders to strategize their business plans accordingly.

TMR researchers conduct exhaustive qualitative and quantitative research. This research involves taking inputs from the experts in the market, focused attention on recent developments, and others. This method of research makes TMR stand out from other market research firms.

Here's how Transparency Market Research helps the stakeholders and CXOs through the reports:

Inculcation and Evaluation of Strategic Collaborations: The TMR researchers analyze recent strategic activities like mergers, acquisitions, partnerships, collaborations, and joint ventures. All the information is compiled and included in the report.

Perfect Market Size Estimations: The report analyzes the demographics, growth potential, and capability of the market through the forecast period. This factor leads to the estimation of the market size and also provides an outline about how the market will retrieve growth during the assessment period.

Investment Research: The report focuses on the ongoing and upcoming investment opportunities across a particular market. These developments make the stakeholders aware of the current investment scenario across the market.

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

4. Market Overview

    4.1. Introduction

        4.1.1. Drug Class Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, 2017–2027

        4.4.1. Market Revenue (US$ Mn) Projection

5. Market Outlook

    5.1. Innovative Solutions for COPD Treatment

    5.2. Pipeline Analysis

6. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast, by Drug Class 

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

        6.3.1. Combination Therapy 

            6.3.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)

            6.3.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)

            6.3.1.3. Triple Therapy

            6.3.1.4. Others

        6.3.2. Corticosteroids

        6.3.3. Bronchodilators

            6.3.3.1. Long Acting Beta Agonist (LABA)

            6.3.3.2. Short Acting Beta Agonist (SABA)

            6.3.3.3. Long Acting Muscarinic Antagonist (LAMA)

        6.3.4. Phosphodiesterase Type 4 Inhibitors

        6.3.5. Mucokinetics

        6.3.6. Others

    6.4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness, by Drug Class 

7. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast, by Distribution Channel 

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027

        7.3.1. Hospital Pharmacies

        7.3.2. Retail Pharmacies

        7.3.3. Online Pharmacies

    7.4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness, by Distribution Channel 

8. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast, by Region

    8.1. Key Findings

    8.2. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Region

        8.2.1. North America 

        8.2.2. Europe 

        8.2.3. Asia Pacific 

        8.2.4. Latin America 

        8.2.5. Middle East & Africa 

    8.3. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness, by region

9. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast

    9.1. Introduction

        9.1.1. Key Findings

    9.2. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

        9.2.1. Combination Therapy 

            9.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)

            9.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)

            9.2.1.3. Triple Therapy

            9.2.1.4. Others

        9.2.2. Corticosteroids

        9.2.3. Bronchodilators

            9.2.3.1. Long Acting Beta Agonist (LABA)

            9.2.3.2. Short Acting Beta Agonist (SABA)

            9.2.3.3. Long Acting Muscarinic Antagonist (LAMA)

        9.2.4. Phosphodiesterase Type 4 Inhibitors

        9.2.5. Mucokinetics

        9.2.6. Others

    9.3. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027

        9.3.1. Hospital Pharmacies

        9.3.2. Retail Pharmacies

        9.3.3. Online Pharmacies

    9.4. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        9.4.1. U.S.

        9.4.2. Canada

    9.5. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis 

        9.5.1. By Drug Class 

        9.5.2. By Distribution Channel 

        9.5.3. By Country/Sub-region

10. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

        10.2.1. Combination Therapy 

            10.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)

            10.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)

            10.2.1.3. Triple Therapy

            10.2.1.4. Others

        10.2.2. Corticosteroids

        10.2.3. Bronchodilators

            10.2.3.1. Long Acting Beta Agonist (LABA)

            10.2.3.2. Short Acting Beta Agonist (SABA)

            10.2.3.3. Long Acting Muscarinic Antagonist (LAMA)

        10.2.4. Phosphodiesterase Type 4 Inhibitors

        10.2.5. Mucokinetics

        10.2.6. Others

    10.3. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027

        10.3.1. Hospital Pharmacies

        10.3.2. Retail Pharmacies

        10.3.3. Online Pharmacies

    10.4. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        10.4.1. Germany

        10.4.2. U.K.

        10.4.3. France

        10.4.4. Spain

        10.4.5. Italy

        10.4.6. Russia

        10.4.7. Rest of Europe

    10.5. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis 

        10.5.1. By Drug Class 

        10.5.2. By Distribution Channel 

        10.5.3. By Country/Sub-region

11. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

        11.2.1. Combination Therapy 

            11.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)

            11.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)

            11.2.1.3. Triple Therapy

            11.2.1.4. Others

        11.2.2. Corticosteroids

        11.2.3. Bronchodilators

            11.2.3.1. Long Acting Beta Agonist (LABA)

            11.2.3.2. Short Acting Beta Agonist (SABA)

            11.2.3.3. Long Acting Muscarinic Antagonist (LAMA)

        11.2.4. Phosphodiesterase Type 4 Inhibitors

        11.2.5. Mucokinetics

        11.2.6. Others

    11.3. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027

        11.3.1. Hospital Pharmacies

        11.3.2. Retail Pharmacies

        11.3.3. Online Pharmacies

    11.4. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        11.4.1. China

        11.4.2. Japan

        11.4.3. India

        11.4.4. Australia & New Zealand

        11.4.5. Rest of Asia Pacific

    11.5. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis 

        11.5.1. By Drug Class 

        11.5.2. By Distribution Channel 

        11.5.3. By Country/Sub-region

12. Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

        12.2.1. Combination Therapy 

            12.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)

            12.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)

            12.2.1.3. Triple Therapy

            12.2.1.4. Others

        12.2.2. Corticosteroids

        12.2.3. Bronchodilators

            12.2.3.1. Long Acting Beta Agonist (LABA)

            12.2.3.2. Short Acting Beta Agonist (SABA)

            12.2.3.3. Long Acting Muscarinic Antagonist (LAMA)

        12.2.4. Phosphodiesterase Type 4 Inhibitors

        12.2.5. Mucokinetics

        12.2.6. Others

    12.3. Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027

        12.3.1. Hospital Pharmacies

        12.3.2. Retail Pharmacies

        12.3.3. Online Pharmacies

    12.4. Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        12.4.1. Brazil

        12.4.2. Mexico

        12.4.3. Rest of Latin America

    12.5. Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis 

        12.5.1. By Drug Class 

        12.5.2. By Distribution Channel 

        12.5.3. By Country/Sub-region

13. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

        13.2.1. Combination Therapy 

            13.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)

            13.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)

            13.2.1.3. Triple Therapy

            13.2.1.4. Others

        13.2.2. Corticosteroids

        13.2.3. Bronchodilators

            13.2.3.1. Long Acting Beta Agonist (LABA)

            13.2.3.2. Short Acting Beta Agonist (SABA)

            13.2.3.3. Long Acting Muscarinic Antagonist (LAMA)

        13.2.4. Phosphodiesterase Type 4 Inhibitors

        13.2.5. Mucokinetics

        13.2.6. Others

    13.3. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027

        13.3.1. Hospital Pharmacies

        13.3.2. Retail Pharmacies

        13.3.3. Online Pharmacies

    13.4. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        13.4.1. GCC 

        13.4.2. South Africa

        13.4.3. Israel

        13.4.4. Rest of Middle East & Africa

    13.5. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis 

        13.5.1. By Drug Class 

        13.5.2. By Distribution Channel 

        13.5.3. By Country/Sub-region

14. Competition Landscape

    14.1. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Player – Competition Matrix (By Tier and Size of companies)

    14.2. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share/ranking Analysis By Company (2018)

    14.3. Company Profiles

        14.3.1. AstraZeneca 

            14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.1.2. Company Financials

            14.3.1.3. Growth Strategies

            14.3.1.4. SWOT Analysis

        14.3.2. Boehringer Ingelheim International GmbH

            14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.2.2. Company Financials

            14.3.2.3. Growth Strategies

            14.3.2.4. SWOT Analysis

        14.3.3. GlaxoSmithKline plc 

            14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.3.2. Company Financials

            14.3.3.3. Growth Strategies

            14.3.3.4. SWOT Analysis

        14.3.4. Novartis AG 

            14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.4.2. Company Financials

            14.3.4.3. Growth Strategies

            14.3.4.4. SWOT Analysis

        14.3.5. Teva Pharmaceutical Industries Ltd. 

            14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.5.2. Company Financials

            14.3.5.3. Growth Strategies

            14.3.5.4. SWOT Analysis

        14.3.6. Sunovion Pharmaceuticals Inc. (Sumitomo Dainippon Pharma Co., Ltd.) 

            14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.6.2. Company Financials

            14.3.6.3. Growth Strategies

            14.3.6.4. SWOT Analysis

        14.3.7. CHIESI Farmaceutici S.p.A. 

            14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.7.2. Company Financials

            14.3.7.3. Growth Strategies

            14.3.7.4. SWOT Analysis

        14.3.8. Orion Corporation 

            14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.8.2. Company Financials

            14.3.8.3. Growth Strategies

            14.3.8.4. SWOT Analysis

        14.3.9. Mylan N.V.

            14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.9.2. Company Financials

            14.3.9.3. Growth Strategies

            14.3.9.4. SWOT Analysis

List of Tables

Table 01: Pipeline Analysis 

Table 02: Pipeline Analysis 

Table 03: Pipeline Analysis 

Table 04: Pipeline Analysis 

Table 05: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 06: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Combination Therapy, 2017–2027

Table 07: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Bronchodilators, 2017–2027

Table 08: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 09: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Region, 2017–2027

Table 10: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 11: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Combination Therapy, 2017–2027

Table 12: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Bronchodilators, 2017–2027

Table 13: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 14: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Country, 2017–2027

Table 15: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 16: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Combination Therapy, 2017–2027

Table 17: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Bronchodilators, 2017–2027

Table 18: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 19: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 20: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 21: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Combination Therapy, 2017–2027

Table 22: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Bronchodilators, 2017–2027

Table 23: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 24: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 25: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 26: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Combination Therapy, 2017–2027

Table 27: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Bronchodilators, 2017–2027

Table 28: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 29: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 30: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 31: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Combination Therapy, 2017–2027

Table 32: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Bronchodilators, 2017–2027

Table 33: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 34: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

List of Figures

Figure 01: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) and Distribution, by Region, 2018 and 2027

Figure 02: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn), by Drug Class, 2018

Figure 03: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 04: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 05: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Combination Therapy, 2017–2027

Figure 06: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Bronchodilators, 2017–2027

Figure 07: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Corticosteroids, 2017–2027

Figure 08: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Phosphodiesterase Type 4 Inhibitor, 2017–2027

Figure 09: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Mucokinetics, 2017–2027

Figure 10: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Others, 2017–2027

Figure 11: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Drug Class, 2019–2027

Figure 12: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2027

Figure 13: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospital Pharmacies, 2017–2027

Figure 14: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Retail Pharmacies, 2017–2027

Figure 15: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Online Pharmacies, 2017–2027

Figure 16: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2019–2027

Figure 17: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Region, 2018 and 2027

Figure 18: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Region, 2019–2027

Figure 19: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 20: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 21: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Drug Class, 2019–2027

Figure 23: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2019–2027

Figure 24: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Country, 2018 and 2027

Figure 25: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Country, 2019–2027

Figure 26: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 27: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 28: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Drug Class, 2019–2027

"Figure 29: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 30: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2019–2027

Figure 31: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 32: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 33: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 34: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 35: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Drug Class, 2019–2027

"Figure 36: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 37: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2019 - 2027

Figure 38: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 39: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 40: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 41: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 42: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Drug Class, 2019–2027

"Figure 43: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 44: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2019 - 2027

Figure 45: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 46: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 47: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 48: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 49: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Drug Class, 2019–2027

"Figure 50: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 51: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2019?2027

Figure 52: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 53: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 54: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share, by Company, 2018

Figure 55: AstraZeneca Respiratory Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2018

Figure 56: AstraZeneca R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016–2018

Figure 57: AstraZeneca Breakdown of Net Sales (%), by Region, 2018

Figure 58: AstraZeneca Breakdown of Net Sales (%), by Product Segment, 2018

Figure 59: Boehringer Ingelheim International GmbH, Human Pharmaceuticals Business Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2018

Figure 60: Boehringer Ingelheim International GmbH R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016–2018

Figure 61: Boehringer Ingelheim International GmbH Breakdown of Net Sales (%), by Region, 2018

Figure 62: Boehringer Ingelheim International GmbH Breakdown of Net Sales (%), by Business Segment, 2018

Figure 63: GlaxoSmithKline plc Respiratory (Pharmaceuticals) Business Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2018

Figure 64: GlaxoSmithKline plc R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016–2018

Figure 65: GlaxoSmithKline plc Breakdown of Net Sales (%), by Region, 2018

Figure 66: GlaxoSmithKline plc Breakdown of Net Sales (%), by Business Segment, 2018

Figure 67: Novartis AG COPD Portfolio Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2018

Figure 68: Novartis AG R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016–2018

Figure 69: Novartis AG Breakdown of Net Sales (%), by Country, 2018

Figure 70: Novartis AG Breakdown of Net Sales (%), by Business Segment, 2018

Figure 71: Teva Pharmaceutical Industries Ltd Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2018

Figure 72: Teva Pharmaceutical Industries Ltd R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016–2018

Figure 73: Teva Pharmaceutical Industries Ltd Breakdown of Net Sales (%), by Geography, 2018

Figure 74: Sumitomo Dainippon Pharma Co., Ltd Pharmaceutical Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2018

Figure 75: Sumitomo Dainippon Pharma Co., Ltd R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016–2018

Figure 76: Sumitomo Dainippon Pharma Co., Ltd Breakdown of Net Sales (%), by Geography, 2018

Figure 77: Sumitomo Dainippon Pharma Co., Ltd Breakdown of Net Sales (%), by Product Segment, 2018

Figure 78: CHIESI Farmaceutici S.p.A. Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2018

Figure 79: CHIESI Farmaceutici S.p.A. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016–2018

Figure 80: CHIESI Farmaceutici S.p.A. Breakdown of Net Sales (%), by Geography, 2018

Figure 81: CHIESI Farmaceutici S.p.A. Breakdown of Net Sales (%), by Therapeutic Area(Business Segment), 2018

Figure 82: Orion Corporation Pharmaceuticals Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2018

Figure 83: Orion Corporation R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016–2018

Figure 84: Orion Corporation Breakdown of Net Sales (%), by Geography, 2018

Figure 85: Orion Corporation Breakdown of Net Sales (%), by Business Segment, 2018

Figure 86: Mylan N.V. Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018

Figure 87: Mylan N.V. Breakdown of Net Sales, by Geography, 2018

Figure 88: Mylan N.V. R&D Expenses (US$ Mn), 2017 and 2018

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Chronic Obstructive Pulmonary Disease Copd Treatment Market